Acurion Bags $4.3 Mn for Oncology Precision Medicine Platform

With the newly acquired funds, Acurion plans to enhance its platform, support clinical validation processes, work towards regulatory approval, and advance commercialization efforts.

Acurion, a San Diego-based provider of AI-driven oncology precision medicine technology, has successfully completed an oversubscribed seed financing round, raising $4.3 million.

The funding round was led by TK & Partners, with contributions from various investors including Mesa Verde Venture Partners, the National Foundation for Cancer Research, the Asian Fund for Cancer Research, and Bootstrap Ventures.

The company's OncoGaze platform is designed to analyze genomic biomarkers from routine clinical slides.

This technology aids clinicians in selecting personalized therapy options for cancer patients. OncoGaze is capable of detecting genomic biomarkers across all cancer types, facilitating real-time therapy decisions.

With the newly acquired funds, Acurion plans to enhance its platform, support clinical validation processes, work towards regulatory approval, and advance commercialization efforts.

"AI has the potential to reshape how we detect and act on cancer biomarkers," said Carey Ng, Ph.D., managing partner at Mesa Verde Venture Partners. "What stood out to us about Acurion is their ability to translate complex science into a solution that fits directly into existing clinical workflows. This is the kind of innovation that can expand access to precision oncology at scale."

Stay tuned for more such updates on Digital Health News